• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Genprex Inc (NQ: GNPX )

    0.3300 UNCHANGED
    Streaming Delayed Price Updated: 3:59 PM EDT, Oct 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 191,718
    Open 0.3300
    Bid (Size) 0.3301 (25)
    Ask (Size) 0.3490 (5)
    Prev. Close 0.3300
    Today's Range 0.3120 - 0.3496
    52wk Range 0.2806 - 16.00
    Shares Outstanding 59,409,822
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Planned Spin-Out to Focus on Gene Therapy for Type-1 and Type-2 Diabetes in Parallel to Treatments for Late Stage Lung Cancer: Genprex, Inc. (Nasdaq: GNPX)
    Via Get News
    Positive Clinical Results with Promising Gene Therapy Treatment for Late Stage Lung Cancer; Life-Changing Developments for Cancer and Diabetes: Genprex, Inc. (Nasdaq: GNPX)
    Via Get News
    Topics Intellectual Property
    Exposures Intellectual Property

    Performance

    YTD
    -96.47%
    -96.47%
    1 Month
    -50.75%
    -50.75%
    3 Month
    -82.72%
    -82.72%
    6 Month
    -89.39%
    -89.39%
    1 Year
    -97.66%
    -97.66%

    More News

    Read More
    Crude Oil Down 2%; Paysafe Shares Surge After Q2 Results
    Via Benzinga
    Exposures Fossil Fuels
    S&P 500 Gains 1%; Home Depot Earnings Top Views
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
    Via Benzinga
    GNPX Stock Earnings: Genprex Reported Results for Q2 2024
    Via InvestorPlace
    GNPX Stock Earnings: Genprex Beats EPS for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Clinical Trials Commenced for Promising Acclaim-3 Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer: Genprex, Inc. (NASDAQ: GNPX)
    Via Get News
    New Company Officers Appointed After Promising Preclinical Data on Gene Therapy for Anti-Tumor Mechanisms with Ability to Trigger Cancer Cell Death: Genprex, Inc. (NASDAQ: GNPX)
    Via Get News
    BioMedNewsBreaks — Genprex Inc. (NASDAQ: GNPX) Announces Participation at Upcoming Investor, Industry Events
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy
    Via Investor Brand Network
    Exposures Product Safety
    BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering
    Via Investor Brand Network
    Exposures Product Safety
    TechMediaBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering
    Via Investor Brand Network
    Exposures Product Safety
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering
    Via Investor Brand Network
    Exposures Product Safety
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering
    Via Investor Brand Network
    Exposures Product Safety
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Adds Korean Patent for Leading Drug Candidate to Growing International Patent Portfolio
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Preclinical Data to be Presented at Upcoming AACR Annual Meeting
    Via Investor Brand Network
    Exposures Product Safety
    BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications
    Via Investor Brand Network
    Exposures Product Safety
    InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications
    Via Investor Brand Network
    Exposures Product Safety
    BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference
    Via Investor Brand Network
    Exposures Product Safety
    BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient
    Via Investor Brand Network
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.